T. Scott Reid
Vice President and Global Head of Companion Diagnostics Discovery Life Sciences
Seminars
Wednesday 7th October 2026
Beating the Clock: Why Early- Phase CTA Strategy Now Decides the Companion Diagnostics Race
11:20 am
- Oncology drug approval timelines are accelerating making contemporaneous development of a companion diagnostic through traditional pathways more challenging
- Our focus will be accelerating early phase development and deployment of novel clinical trial assays, with early access to solutions that enable fast decision making and clinical trial startup
- Integrating digital pathology and AI solutions into IHC assay development to get more bang for your biomarker buck
